186 related articles for article (PubMed ID: 35357901)
21. Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M; Blumenberg V; Rejeski K; Bücklein VL; Ruzicka M; Unterrainer M; Schmidt C; Dekorsy FJ; Bartenstein P; Ricke J; von Bergwelt-Baildon M; Subklewe M; Kunz WG
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1406-1413. PubMed ID: 36513818
[TBL] [Abstract][Full Text] [Related]
22. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL.
Mikhaeel NG; Smith D; Dunn JT; Phillips M; Møller H; Fields PA; Wrench D; Barrington SF
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1209-19. PubMed ID: 26902371
[TBL] [Abstract][Full Text] [Related]
23. A better prediction of progression-free survival in diffuse large B-cell lymphoma by a prognostic model consisting of baseline TLG and %ΔSUV
Zhang YY; Song L; Zhao MX; Hu K
Cancer Med; 2019 Sep; 8(11):5137-5147. PubMed ID: 31343111
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of clinical characteristics and
Liu Y; Jiang J; Liu L; Wang Z; Yu B; Xia Z; Zhang Q; Ji D; Liu X; Lv F; Hong X; Song S; Cao J
J Int Med Res; 2022 Jan; 50(1):3000605211063027. PubMed ID: 35001690
[TBL] [Abstract][Full Text] [Related]
25. [Value of
Zhang YY; Chen WY; Cui YP; Gao XR; Hu JX; Li ZZ; Hu K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1342-1249. PubMed ID: 30295248
[TBL] [Abstract][Full Text] [Related]
26. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma.
Eertink JJ; Zwezerijnen GJC; Heymans MW; Pieplenbosch S; Wiegers SE; Dührsen U; Hüttmann A; Kurch L; Hanoun C; Lugtenburg PJ; Barrington SF; Mikhaeel NG; Ceriani L; Zucca E; Czibor S; Györke T; Chamuleau MED; Hoekstra OS; de Vet HCW; Boellaard R; Zijlstra JM
Blood; 2023 Jun; 141(25):3055-3064. PubMed ID: 37001036
[TBL] [Abstract][Full Text] [Related]
27. Baseline
Aide N; Fruchart C; Nganoa C; Gac AC; Lasnon C
Eur Radiol; 2020 Aug; 30(8):4623-4632. PubMed ID: 32248365
[TBL] [Abstract][Full Text] [Related]
28. Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.
Miyazaki Y; Nawa Y; Miyagawa M; Kohashi S; Nakase K; Yasukawa M; Hara M
Ann Hematol; 2013 Jan; 92(2):239-44. PubMed ID: 23079891
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.
Xie M; Wu K; Liu Y; Jiang Q; Xie Y
Med Oncol; 2015 Jan; 32(1):446. PubMed ID: 25511321
[TBL] [Abstract][Full Text] [Related]
30. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
31. A novel prognostic index for diffuse large B-cell lymphoma combined baseline metabolic tumour volume with clinical and pathological risk factors.
Yuan T; Chen X; Zhang Y; Wei M; Zhu H; Yang Z; Wang X
Nucl Med Commun; 2023 Jul; 44(7):622-630. PubMed ID: 37114393
[TBL] [Abstract][Full Text] [Related]
32. Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-center experience.
Campiotti L; DE Palma D; Guasti L; Proserpio I; Casagrande S; Schiorlin I; Bolzacchini E; Suter M; Ogliari F; Squizzato A
Q J Nucl Med Mol Imaging; 2021 Mar; 65(1):59-63. PubMed ID: 30781938
[TBL] [Abstract][Full Text] [Related]
33. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.
Ilyas H; Mikhaeel NG; Dunn JT; Rahman F; Møller H; Smith D; Barrington SF
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1142-1154. PubMed ID: 29460024
[TBL] [Abstract][Full Text] [Related]
34. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma.
Kim TM; Paeng JC; Chun IK; Keam B; Jeon YK; Lee SH; Kim DW; Lee DS; Kim CW; Chung JK; Kim IH; Heo DS
Cancer; 2013 Mar; 119(6):1195-202. PubMed ID: 23212736
[TBL] [Abstract][Full Text] [Related]
35. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
36. PET/CT Biomarkers Enable Risk Stratification of Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Enrolled in the LOTIS-2 Clinical Trial.
Alderuccio JP; Reis IM; Hamadani M; Nachiappan M; Leslom S; Kahl BS; Ai WZ; Radford J; Solh M; Ardeshna KM; Hess BT; Lunning MA; Zinzani PL; Stathis A; Carlo-Stella C; Lossos IS; Caimi PF; Han S; Yang F; Kuker RA; Moskowitz CH
Clin Cancer Res; 2024 Jan; 30(1):139-149. PubMed ID: 37855688
[TBL] [Abstract][Full Text] [Related]
37. Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Rojek AE; Kline JP; Feinberg N; Appelbaum DE; Pu Y; Derman BA; Jakubowiak A; Kosuri S; Liu H; Nawas MT; Smith SM; Bishop MR; Riedell PA
Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):83-93. PubMed ID: 37827881
[TBL] [Abstract][Full Text] [Related]
38. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
39. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
[TBL] [Abstract][Full Text] [Related]
40. Tumor and bone marrow uptakes on [18F]fluorodeoxyglucose positron emission tomography/computed tomography predict prognosis in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy.
Chang CC; Cho SF; Tu HP; Lin CY; Chuang YW; Chang SM; Hsu WL; Huang YF
Medicine (Baltimore); 2017 Nov; 96(45):e8655. PubMed ID: 29137104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]